High DHEA, estradiol tied to lower EA/GCA risk in men

  • Petrick JL & al.
  • J Natl Cancer Inst
  • 17 May 2018

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Men with higher prediagnostic levels of circulating dehydroepiandrosterone (DHEA) and estradiol have a 34%-38% lower risk for esophageal adenocarcinoma (EA) and gastric cardia adenocarcinoma (GCA), the first evidence of an association of these sex hormones and reduced EA/GCA risk.

Why this matters

  • Age-adjusted EA/GCA rates are 4-8 times higher in men than women.  

Study design

  • 259 patients with EA/GCA and 259 control participants, all male, pooled from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; and Cancer Prevention Study II Nutrition Cohort.
  • Funding: National Institutes of Health.

Key results

  • A doubling in circulating concentration of DHEA was associated with a 38% lower EA/GCA risk (OR per 1-unit increase in log2 DHEA, 0.62; 95% CI, 0.47-0.82).
  • A doubling in circulating concentration of estradiol was associated with a 34% lower EA/GCA risk (OR per 1-unit increase in log2 estradiol, 0.66; 95% CI, 0.45-0.98).
  • Associations remained significant after multivariable adjustment.

Limitations

  • Too few women to study the association between female sex hormones and cancer risk.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit